Stock comparison
ResMed
Bio-Techne
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
TECH
Bio-Techne
Market cap
$7.55B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | RMD | TECH | Winner |
|---|---|---|---|
| Warren Buffett | 72B | 55C | RMD |
| Benjamin Graham | 75B | 89A | TECH |
| Philip Fisher | 75B | 50C | RMD |
| Peter Lynch | 58C | 24F | RMD |
| Joel Greenblatt | 47D | 50D | TECH |
| Charlie Munger | 69B | 45D | RMD |
| Terry Smith | 73B | 44D | RMD |
Side-by-side metrics
| Metric | RMD | TECH |
|---|---|---|
| Market cap | $30.18B | $7.55B |
| P/E (TTM) | 19.6x | 61.6x |
| EV/EBIT | 17.1x | 67.1x |
| ROIC (TTM) | 19.63% | 4.75% |
| Gross margin | 61.69% | 64.96% |
| Net margin | 27.44% | 9.05% |
| Revenue CAGR 5y | 12.64% | 6.98% |
| EPS CAGR 5y | 30.73% | -15.23% |
| Debt / Equity | 0.1x | 0.1x |
| Dividend yield | 1.14% | 0.74% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
RMD leads on
- EPS CAGR 5y30.73%vs -15.23%+150%
- ROIC (TTM)19.63%vs 4.75%+76%
- Market cap$30.18Bvs $7.55B+75%
- EV/EBIT17.1xvs 67.1x+75%
TECH leads on
- Gross margin64.96%vs 61.69%+5%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.